Mylan Makes Its Move, Buys Abbott Generics In Tax Inversion Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.